Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?

Amgen posted FY 2025 revenue of nearly $36.8B, net income of $7.7B, and free cash flow of about $8.1B, while NovoCure generated $655.4M of revenue but remained unprofitable with a $136.2M net loss and negative free cash flow of $75.7M. The article favors Amgen for its scale, profitability, and $9.80 annual dividend, despite regulatory and legal risks, while noting NovoCure’s FDA-approved expansion but longer funding runway and slower path to cash flow. Overall, it is a comparative stock-picking piece with modestly positive lean toward Amgen rather than a major company-specific catalyst.

Analysis

AMGN is the cleaner balance-sheet-to-cash-flow story, but the more important second-order effect is that its scale gives it optionality that the market is likely understating: in pharma, excess cash is not just defensive, it is a call option on late-stage assets, tuck-in M&A, and repurchases when sentiment turns. The combination of high free cash flow and a mature franchise also makes AMGN unusually resilient if pricing pressure bites, because management can defend EPS through capital returns and portfolio optimization rather than relying on single-product growth.

NVCR’s problem is not that the technology is uninteresting; it is that the commercialization pathway creates a long-duration funding overhang. A direct-to-patient model sounds disintermediating, but in practice it shifts risk from wholesalers to payers, where reimbursement friction can turn revenue growth into working-capital drag and margin volatility. If adoption accelerates after the new indication, the near-term winner may still be contract manufacturers, clinical support vendors, and reimbursement consultants rather than equity holders, because incremental scale is likely to be reinvested into commercialization rather than dropped to FCF.

The consensus may be overdiscounting AMGN’s “slow grower” label and underdiscounting NVCR’s dilution risk over the next 12-24 months. AMGN’s valuation embeds a lot of maturity, but its dividend and earnings power can support multiple expansion if the market rotates back toward cash-generative defensives. By contrast, NVCR only becomes compelling if coverage wins arrive fast enough to bridge the cash burn window; absent that, each positive clinical headline can paradoxically weaken the equity by extending the runway needed before self-funding is visible.

Key Decisions for Investors

• Long AMGN vs short NVCR as a 6-12 month pair trade: favor the asset with near-term self-funding and buyback/dividend support over the one still dependent on external capital.
• Buy AMGN on any 3-5% pullback with a 9-12 month horizon; target total return is dividend plus modest multiple re-rating, with downside cushioned by FCF conversion.
• Sell out-of-the-money NVCR calls or use a call spread overlay into any FDA-approval-driven strength; the setup looks like a 'good news, better financing terms' catalyst rather than a straight-line rerate.
• If you want exposure to NVCR, wait for payer/coverage milestones, not product headlines; the trade is only attractive once reimbursement de-risks the path to 2028 FCF breakeven.